A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2017 Results published in an Acetelion Pharmaceuticals media release.
    • 23 Jan 2017 Primary endpoint has not been met. (Change from baseline to Week 16 in exercise capacity, as measured by 6MWD), as per an Acetelion Pharmaceuticals media release.
    • 21 Dec 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top